A Phase IB Multicentre, Open-label Study To Determine The Recommended Dose And Regimen Of Durvalumab (MEDI4736) Either As Monotherapy or In Combination With Pomalidomide (POM) With Or Without Low-Dose Dexamethasone (DEX) In Subjects With Relapsed And Refractory Multiple Myeloma (RRMM)
This is a multicentre, multicountry, open-label, Phase 1b study for dose finding as well as
parallel cohort dose expansion(s) to determine the recommended dose and regimen of
durvalumab either as monotherapy or in combination with pomalidomide (POM) with or without
low dose dex in subjects with Relapsed and Refractory Multiple Myeloma (RRMM). The study
will consist of a dose-finding portion as well as a parallel dose expansion portion to
determine the optimal dose and regimen.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society